Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

, CELG

Celgene

$118.51

-3.62 (-2.96%)

17:29
11/30/16
11/30
17:29
11/30/16
17:29

bluebird bio 'pleased' with early data from Phase 1 study of bb2121

bluebird bio (BLUE) announced that interim data from its ongoing Phase 1 clinical study of bb2121, the company's investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma, will be presented on Thursday, December 1, 2016 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany. bluebird bio is developing bb2121 in collaboration with Celgene Corporation (CELG). "We are pleased that these early data from our ongoing Phase 1 study of bb2121 demonstrate objective anti-tumor responses in heavily pre-treated patients with multiple myeloma, with all patients in the 15.0 x 107 and 45.0 x 107 CAR+ T cell dose cohorts achieving responses, including among them, patients with stringent complete responses and elimination of minimal residual disease," said David Davidson, M.D., chief medical officer, bluebird bio. "We are also encouraged by the safety profile to date, particularly the lack of severe cytokine release syndrome or neurotoxicity. In light of these positive data, and thanks to the multiple participating clinical sites and centralized manufacturing infrastructure we and our partner Celgene have built for this program, we anticipate efficiently completing the dose escalation stage of the trial and initiating the expansion cohort."

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

CELG

Celgene

$118.51

-3.62 (-2.96%)

  • 30

    Nov

  • 30

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
11/23/16
11/23/16
NO CHANGE

Buy
bluebird bio weakness unwarranted after Juno trial halt, says Janney Capital
As previously reported, Janney Capital analyst Debjit Chattopadhyay said the weakness in bluebird bio (BLUE) is unwarranted on the heels of Juno's (JUNO) second clinical hold for JCAR015. Chattopadhyay notes several key differences between JCAR015 and bluebird's bb2121, including their targets, diseases, vectors, preconditioning regimens and others. He remains a buyer of bluebird ahead of a "potentially watershed ASH for its lentiglobin platform" and keeps a Buy rating on the stock.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
CELG Celgene
$118.51

-3.62 (-2.96%)

11/09/16
STPT
11/09/16
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/28/16
OPCO
11/28/16
INITIATION
Target $141
OPCO
Outperform
Celgene initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Cann initiated Celgene with an Outperform rating and $141 price target, estimating that revenue will grow at a compound annual growth rate of 19% per year for the next five years and that its GAAP EPS can grow by a 31% CAGR over the same span.

TODAY'S FREE FLY STORIES

JHG

Janus Henderson Group

$33.96

0.42 (1.25%)

05:39
09/25/17
09/25
05:39
09/25/17
05:39
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMES

Emerge Energy

$9.17

0.44 (5.04%)

05:36
09/25/17
09/25
05:36
09/25/17
05:36
Initiation
Emerge Energy initiated  »

Emerge Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.10

0.3 (3.06%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Initiation
Hi-Crush Partners initiated  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34
Hot Stocks
Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective »

Exelixis (EXEL) announced…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

VFC

VF Corp.

$62.20

0.35 (0.57%)

, UAA

Under Armour

$16.41

-0.08 (-0.49%)

05:31
09/25/17
09/25
05:31
09/25/17
05:31
Downgrade
VF Corp., Under Armour, Under Armour rating change  »

VF Corp. downgraded to…

VFC

VF Corp.

$62.20

0.35 (0.57%)

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

UAA

Under Armour

$16.41

-0.08 (-0.49%)

, UA

Under Armour

$15.04

-0.09 (-0.59%)

05:28
09/25/17
09/25
05:28
09/25/17
05:28
Upgrade
Under Armour, Under Armour, VF Corp. rating change  »

Under Armour upgraded to…

UAA

Under Armour

$16.41

-0.08 (-0.49%)

UA

Under Armour

$15.04

-0.09 (-0.59%)

VFC

VF Corp.

$62.20

0.35 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$13.70

-0.07 (-0.51%)

05:24
09/25/17
09/25
05:24
09/25/17
05:24
Recommendations
Snap analyst commentary  »

Snap price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$60.10

-9.4 (-13.53%)

05:20
09/25/17
09/25
05:20
09/25/17
05:20
Upgrade
Compass Minerals rating change  »

Compass Minerals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

COR

CoreSite Realty

$108.49

-1.86 (-1.69%)

05:18
09/25/17
09/25
05:18
09/25/17
05:18
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ROST

Ross Stores

$60.89

-0.02 (-0.03%)

05:17
09/25/17
09/25
05:17
09/25/17
05:17
Upgrade
Ross Stores rating change  »

Ross Stores upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFC

Corporate Office Properties

$32.53

-0.13 (-0.40%)

05:11
09/25/17
09/25
05:11
09/25/17
05:11
Upgrade
Corporate Office Properties rating change  »

Corporate Office…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMRF

ABN Amro

05:08
09/25/17
09/25
05:08
09/25/17
05:08
Upgrade
ABN Amro rating change  »

ABN Amro upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$39.42

0.32 (0.82%)

05:05
09/25/17
09/25
05:05
09/25/17
05:05
Upgrade
General Motors rating change  »

General Motors upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGLOY

Anglo American

$9.12

-0.1 (-1.08%)

04:59
09/25/17
09/25
04:59
09/25/17
04:59
Downgrade
Anglo American rating change  »

Anglo American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$36.57

0.45 (1.25%)

04:56
09/25/17
09/25
04:56
09/25/17
04:56
Downgrade
Butterfield rating change  »

Butterfield downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$2.68

-18.925 (-87.62%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

HSC

Harsco

$19.75

0.35 (1.80%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

IIVI

II-VI

$40.40

0.45 (1.13%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

AMCX

AMC Networks

$59.08

0.14 (0.24%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
AMC Networks management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

September Dallas Fed Mfg…

04:55
09/25/17
09/25
04:55
09/25/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

ARKAY

Arkema

$121.34

-0.06 (-0.05%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Arkema management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

HES

Hess Corp.

$44.50

0.87 (1.99%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

DNOW

NOW Inc.

$12.99

0.01 (0.08%)

04:55
09/25/17
09/25
04:55
09/25/17
04:55
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.